As the first oral SMN2 splicing modifier, Risdiplam Tablets (Evrysdi) provide an innovative treatment option for patients with spinal muscular atrophy (SMA).

How to Use Risdiplam Tablets (Evrysdi)

1. Routine Administration Methods

(1) Swallow Whole: Take the entire tablet with an appropriate amount of water. Chewing, cutting, or crushing the tablet is prohibited.

(2) Dispersed Administration: Dissolve the tablet in 5 mL of room-temperature non-chlorinated drinking water (e.g., filtered water). Gently stir for up to 3 minutes until fully dispersed (a small amount of particles may remain). The dispersion must be consumed within 10 minutes. To ensure the full dose is taken, rinse the container with 15 mL of water and drink the rinse water.

2. Key Operational Points

(1) The prepared dispersion must be used within 10 minutes.

(2) Administration of the dispersion via nasogastric tube or gastrostomy tube is prohibited (a dedicated oral solution dosage form must be used for tube feeding).

(3) Take the medication at a fixed time every day, either with food or on an empty stomach.

(4) Avoid contact of the medication with skin or eyes. If contact occurs, immediately rinse with soapy water/clean water.

3. Management of Abnormal Situations

(1) Missed Dose: If a missed dose is noticed within 6 hours, take it immediately. If more than 6 hours have passed, skip the missed dose and take the next dose as scheduled the next day.

(2) Vomiting treatment: Vomiting after taking the medicine should not be refilled, and wait until the next day for normal administration.

Dosage Adjustment of Risdiplam Tablets (Evrysdi)

1. Adjustment for Special Conditions

(1) Hepatic Impairment: No dosage adjustment is required for mild to moderate impairment; careful evaluation is needed for severe hepatic impairment.

(2) Renal Impairment: Current data indicate no dosage adjustment is necessary.

(3) Elderly Patients: Individualized dosing based on overall health status is recommended.

2. Principles for Dosage Form Selection

(1) The oral solution is suitable for patients of all age groups.

(2) The tablet (5 mg) is only suitable for patients aged ≥ 2 years and with a body weight ≥ 20 kg.

Medication for Special Populations with Risdiplam Tablets (Evrysdi)

1. Pregnant Women

(1) Animal studies have shown embryotoxicity, which may cause malformations.

(2) Pregnancy testing must be performed before initiating medication.

(3) Effective contraceptive measures must be used during treatment and for 1 month after discontinuing the medication.

2. Lactating Women

(1) The drug may be excreted in breast milk.

(2) The necessity of treatment should be weighed to decide whether to suspend breastfeeding.

3. Reproductive-Age Population

(1) Male Patients: May affect fertility; sperm preservation should be considered before treatment.

(2) Female Patients: Reliable contraceptive measures must be used during treatment.